Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL). The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lapalombella, Rosa, Yu, Bo, Triantafillou, Georgia, Liu, Qing, Butchar, Jonathan P., Lozanski, Gerard, Ramanunni, Asha, Smith, Lisa L., Blum, William, Andritsos, Leslie, Wang, Da-Sheng, Lehman, Amy, Chen, Ching-Shih, Johnson, Amy J., Marcucci, Guido, Lee, Robert J., Lee, L. James, Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597613/
https://ncbi.nlm.nih.gov/pubmed/18772452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-01-133108
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak